Le Lézard
Classified in: Health
Subjects: PDT, MAT

InventHelp Inventor Develops Transporter for Biological Material from a Miscarriage (LBT-9019)


PITTSBURGH, March 17, 2025 /PRNewswire/ -- "I'm a paramedic, and I wanted to create a product that would allow a woman to transport a fetus in the event of a miscarriage to a hospital, lab, mortuary, or other location," said an inventor, from Shawnee, Kan., "so I invented the ANGEL WING. My design would provide added respect during a serious, sensitive, and heart-breaking time."

The patent-pending invention provides an improved means to transport a miscarried fetus. In doing so, it can be easily deployed during a miscarriage. It also provides respect during a sensitive time. As a result, it offers an alternative to traditional means of transport or disposal. The invention features a compact design that is easy to use so it is ideal for pregnant women who are at high risk for complications, various medical providers such as ambulances, obstetricians/gynecologists, and emergency rooms, etc. Additionally, a prototype model and technical drawings are available upon request.

The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 23-LBT-9019, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp


These press releases may also interest you

at 23:09
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or "Company") is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2025 (the "MCTO"), by its principal regulator, the British Columbia Securities...

at 23:00
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now available in the United States. This marks a significant...

at 21:00
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.7 billion (USD 11.4 million1) in five projects for the development of schistosomiasis diagnostics and drugs for neglected tropical diseases...

at 19:37
Telix Pharmaceuticals Limited  today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company's...

at 18:00
TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for HIV maintenance therapy. This regimen, which is the first of its kind, offers a viable...

at 17:46
A global pharmaceutical company, having recently acquired a mid-cap biotech firm, sought to evaluate the market value of a newly obtained oncology asset. The drug, part of an emerging class of immune checkpoint inhibitor therapies, demonstrated...



News published on and distributed by: